Skip to main content

An acceptable risk? Use of Lariam for military personnel

6 November 2015

Defence Committee hold first evidence session for their inquiry into the use of Lariam by military personnel.


Tuesday 10 November 2015, Committee Room 15, Palace of Westminster

At 11.30am

  • Dr Frances Nichol, Head of Drug Safety Quality, Roche
  • Mike Kindell, Lead, Established Products, Roche

Purpose of the session

The purpose of the session is to question Roche, the main producer of Lariam in the UK, on general information relating to Lariam as an anti-malarial drug; the conditions of the use of Lariam and its side effects; the use of Lariam by the military and research on the risks to the military of using Lariam.

Further information